Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy
Bhavana Bhatnagar(The Ohio State University), Maria R. Baer(University of Maryland, Baltimore), Theodore Stewart Gourdin, Ching Chen(University of Maryland, Baltimore), Yi Ning(University of Maryland, Baltimore), Michael L. Tidwell(University of Maryland, Baltimore), Vu H. Duong(University of Maryland, Baltimore), Edward A. Sausville(University of Maryland, Baltimore), Ashkan Emadi(University of Maryland, Baltimore)
Cited by 56
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764